Soft Tissue Sarcoma, Version 2.2012
Margaret von Mehren, Robert S. Benjamin, Marilyn M. Bui et al. · Journal of the National Comprehensive Cancer Network · 2012
The major changes to the 2012 and 2011 NCCN Guidelines for Soft Tissue Sarcoma pertain to the management of patients with gastrointestinal stromal tumors (GISTs) and desmoid tumors (aggressive fibromatosis). Postoperative imatinib following complete resection for primary GIST with no preoperative imatinib is now included as a category 1 recommendation for patients with intermediate or high risk of recurrence. The panel also reaffirmed the recommendation for preoperative use of imatinib in patients with GISTs that are resectable with negative margins but associated with significant surgical morbidity. Observation was included as an option for patients with resectable desmoid tumors that are small and asymptomatic, not causing morbidity, pain, or functional limitation. Sorafenib is included as an option for systemic therapy for patients with desmoid tumors.
Cited by 150 works. doi:10.6004/jnccn.2012.0099 Open-access PDF
Authors
- Margaret von Mehren
- Robert S. Benjamin
- Marilyn M. Bui
- Ephraim S. Casper
- Ernest U. Conrad
- Thomas F. DeLaney
- Kristen Nooshin Ganjoo
- Suzanne George
- Ricardo González
- Martin J. Heslin
- John Michael Kane
- Joel L. Mayerson
- Sean V. McGarry
- Christian Frederick Meyer
- Richard J. O’Donnell
- Benjamin I Paz
- John D. Pfeifer
- Raphael E. Pollock
- Robert Lor Randall
- Richard F. Riedel
References
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
- Two Hundred Gastrointestinal Stromal Tumors
- PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
- NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
- KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
- Risk stratification of patients diagnosed with gastrointestinal stromal tumor
- Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors